New analysis of Phase II data at AACR assesses ImaginAb’s investigational CD8 ImmunoPET technology’s ability to predict response in immunotherapy

Posted on by

LOS ANGELES, April 14, 2023 /PRNewswire/ — ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical therapies (RPT) announces a poster presentation at AACR 2023 (# 3577 / 2 Poster PET, MRI, and CT Imaging…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.